BR112013006344A2 - lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas - Google Patents

lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas

Info

Publication number
BR112013006344A2
BR112013006344A2 BR112013006344A BR112013006344A BR112013006344A2 BR 112013006344 A2 BR112013006344 A2 BR 112013006344A2 BR 112013006344 A BR112013006344 A BR 112013006344A BR 112013006344 A BR112013006344 A BR 112013006344A BR 112013006344 A2 BR112013006344 A2 BR 112013006344A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
substituted lactams
preparing same
gpr119
modulators
Prior art date
Application number
BR112013006344A
Other languages
English (en)
Inventor
Ajay Singh
Jay Bradford Fell
John P Fischer
Josef R Bencsik
Kevin Ronald Condroski
Ronald Jay Hinklin
Scott Alan Pratt
Steven Armen Boyd
Thomas Daniel Aicher
Timothy M Turner
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of BR112013006344A2 publication Critical patent/BR112013006344A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

lactamas substituídas por piperdinila como moduladores de gpr119. a presente invenção refere-se a compostos de fórmula (i) e a sais farmaceuticamente aceitáveis dos mesmos, nos quais x^ 1^, x^ 2^, l, r^ 3^, r^ 4, r^ 5^, r^ 7^ e n têm os significados dados no relatório descritivo, que são moduladores de gpr119 e são úteis no tratamento ou na prevenção de doenças, tais como, mas não limitadas a, diabetes do tipo 2, complicações diabéticas, sintomas de diabetes, metabólica, obesidade, dislipidemia e condições relacionadas.
BR112013006344A 2010-09-17 2011-09-15 lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas BR112013006344A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38379910P 2010-09-17 2010-09-17
PCT/US2011/051821 WO2012037393A1 (en) 2010-09-17 2011-09-15 Piperidinyl-substituted lactams as gpr119 modulators

Publications (1)

Publication Number Publication Date
BR112013006344A2 true BR112013006344A2 (pt) 2016-06-21

Family

ID=44736053

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013006344A BR112013006344A2 (pt) 2010-09-17 2011-09-15 lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas

Country Status (18)

Country Link
US (1) US20130184257A1 (pt)
EP (1) EP2616074A1 (pt)
JP (1) JP2013537234A (pt)
KR (1) KR20130099970A (pt)
CN (1) CN103221046A (pt)
AR (1) AR083003A1 (pt)
AU (1) AU2011301934A1 (pt)
BR (1) BR112013006344A2 (pt)
CA (1) CA2811525A1 (pt)
CL (1) CL2013000714A1 (pt)
CR (1) CR20130173A (pt)
IL (1) IL225214A0 (pt)
MX (1) MX2013003034A (pt)
RU (1) RU2013117403A (pt)
SG (1) SG188985A1 (pt)
TW (1) TW201213322A (pt)
UY (1) UY33614A (pt)
WO (1) WO2012037393A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012013465A (es) 2010-05-17 2013-12-02 Array Biopharma Inc Lactamas sustituidas con piperidinilo como moduladores de gpr119.
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
DK2780015T3 (en) 2011-11-18 2017-03-27 Heptares Therapeutics Ltd M1 MUSCARINRECEPTORAGONISTER
CN104780915A (zh) 2012-07-11 2015-07-15 埃尔舍利克斯治疗公司 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物
AR092924A1 (es) 2012-10-09 2015-05-06 Sanofi Sa Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
US9896434B2 (en) 2014-04-04 2018-02-20 Sanofi Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
AR099936A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
AR099937A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CN104892517A (zh) * 2015-02-13 2015-09-09 佛山市赛维斯医药科技有限公司 酰肼类化合物、其制备方法及用途
CN104610151A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 含酰肼和烷氧苯类结构的化合物、其制备方法及用途
CN104672116B (zh) * 2015-02-13 2016-06-01 佛山市赛维斯医药科技有限公司 一种含苯磺酰肼和腈基苯结构gpr119激动剂及其用途
UY36586A (es) 2015-03-26 2016-10-31 Bayer Pharma AG Heterociclilmetiltienouracilos y uso de los mismos
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
AR110988A1 (es) 2017-02-21 2019-05-22 Sanofi Sa Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
WO2008025799A1 (en) * 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyridazine compounds for treating gpr119 related disorders
EP2321308B9 (en) * 2008-07-10 2012-08-08 Prosidion Limited Piperidine gpcr agonists

Also Published As

Publication number Publication date
KR20130099970A (ko) 2013-09-06
RU2013117403A (ru) 2014-10-27
EP2616074A1 (en) 2013-07-24
AU2011301934A1 (en) 2013-05-16
CA2811525A1 (en) 2012-03-22
UY33614A (es) 2013-04-05
CR20130173A (es) 2013-05-15
MX2013003034A (es) 2013-08-15
CN103221046A (zh) 2013-07-24
JP2013537234A (ja) 2013-09-30
US20130184257A1 (en) 2013-07-18
WO2012037393A1 (en) 2012-03-22
IL225214A0 (en) 2013-06-27
CL2013000714A1 (es) 2013-10-11
AR083003A1 (es) 2013-01-23
SG188985A1 (en) 2013-05-31
TW201213322A (en) 2012-04-01

Similar Documents

Publication Publication Date Title
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112012029395A2 (pt) lactamas piperdinil-substituídas como moduladores de gpr119
BR112015007182A2 (pt) inibidores de gdf-8
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
EA201491335A1 (ru) Бигуанидные композиции и способы лечения метаболических расстройств
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BRPI0922220A8 (pt) Uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
BR112013021236A2 (pt) composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
BRPI0915592A2 (pt) composto agonista do receptor de gpr119, processo para a preparação do composto, composição farmacêutica que o compreende, uso do mesmo e método para o tratamento ou profilaxia de diabetes mellitus do tipo ii
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
BR112012014180A2 (pt) composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
BR112013000107A2 (pt) aminopirazoloquinazolinas
BR112012007102A2 (pt) compostos policíclicos como antagonistas de receptores do ácido lisofosfatpidico
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
BR112014031091A2 (pt) Derivados de piperidina para agonista de gpr119

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]